This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 969764 results found since Jan 2013.

Disease-modifying treatments for progressive multiple sclerosis
The last 20 years have seen major progress in the treatment of relapsing–remitting multiple sclerosis (RRMS) using a variety of drugs targeting immune dysfunction. In contrast, all clinical trials of such agents in primary progressive multiple sclerosis (PPMS) have failed and there is limited evidence of their efficacy in secondary progressive disease. Evolving concepts of the complex interplay between inflammatory and neurodegenerative processes across the course of multiple sclerosis (MS) may explain this discrepancy. This paper will provide an up-to-date overview of the rationale and results of the published clini...
Source: Multiple Sclerosis - September 23, 2013 Category: Neurology Authors: Comi, G. Tags: Topical Review Source Type: research

Exercising away the blues: can it help multiple sclerosis-related depression?
The present review focuses on exercise as a treatment for depression in multiple sclerosis. While exercise has emerged as a potentially useful treatment in the general psychiatry-depression literature, the findings from a small number of multiple sclerosis-related treatment trials are equivocal. Methodological limitations, including the absence of depression as a primary endpoint, characterize all the studies completed to date. Given that limitations in study design can be rectified, it is time to put exercise to the test once more. Depressed multiple sclerosis patients and those involved in their care are looking for guid...
Source: Multiple Sclerosis - November 25, 2013 Category: Neurology Authors: Feinstein, A., Rector, N., Motl, R. Tags: Topical Review Source Type: research

Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan
The need for improved clinical outcome measures in multiple sclerosis trials has been recognized for two decades, but only recently has the Food and Drug Administration (FDA) created a pathway for qualification of new clinician-reported outcome (ClinRO) assessments. Additionally, drug development in multiple sclerosis (MS) has been extraordinarily active, with numerous disease-modifying drugs now on the market. This shifting therapeutic landscape, along with the unmet need for drugs to treat the progressive forms of MS and the changing expectations of clinicians, patients, and payers, have led to the call for more sensitiv...
Source: Multiple Sclerosis - December 17, 2013 Category: Neurology Authors: Rudick, R. A., LaRocca, N., Hudson, L. D., MSOAC Tags: Meeting Review Source Type: research

Obesity and birth control pills may increase risk of multiple sclerosis
Approximately 2.5 million people worldwide are living with multiple sclerosis and 200 people are diagnosed with the disease every day. Now, two new studies suggest that the "obesity hormone" leptin and hormones used in birth control pills may increase the risk of multiple sclerosis.The findings will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, PA, in April.Multiple sclerosis (MS) is a disease of the central nervous system. Onset of the condition is most common between the ages of 20 and 40.
Source: Health News from Medical News Today - February 28, 2014 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

Multiple sclerosis: raising awareness of a complex disease
What do you know about multiple sclerosis? Chances are, very little. "Many people aren't aware of the symptoms of multiple sclerosis, or even of the condition itself," says Dr. Emma Gray. Considering that approximately 2.5 million people around the world have multiple sclerosis, it is surprising that there is such lack of awareness, but sadly, this is the case.Dr.
Source: Health News from Medical News Today - March 21, 2014 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis
Conclusion: In patients with MS, sexual dysfunction has a much larger detrimental impact on the mental health aspects of HrQoL than severity of physical disability.
Source: Multiple Sclerosis - April 1, 2014 Category: Neurology Authors: Schairer, L. C., Foley, F. W., Zemon, V., Tyry, T., Campagnolo, D., Marrie, R. A., Gromisch, E. S., Schairer, D. Tags: Research Papers Source Type: research

Gustatory Dysfunction in Multiple Sclerosis (P6.159)
CONCLUSIONS:MS was associated with taste dysfunction on both the front and back of the tongue in about one-fifth of the patients. Lesion activity, in some brain regions, was correlated with the magnitude of the deficits for some taste stimuli. Importantly, all classical taste qualities are affected, with a slightly greater influence on tastants that employ transduction mechanisms that directly gate membrane channel receptors.Study Supported by:NIH RO1 DC 02974, NIH R01 NS 37172, and DOD W81XWH-09-1-0467.Disclosure: Dr. Doty has received personal compensation for activities with Sensonics, Inc. Adams & Adams, Christophe...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Doty, R., Tourbier, I., Leon-Sarmiento, F., Udupa, J., Karacali, B., Moonis, G., Beals, E., Fabius, L., Kim, T., Palecanda, B., Souza, A. Tags: Multiple Sclerosis Symptoms and Comorbidities Source Type: research

Multiple Sclerosis Patients with Allergies Demonstrate Better Physical Outcomes but Worse Psychological Symptoms. (P6.172)
CONCLUSION: Coexistence of allergies may provide a better physical outcome in MS patients Our findings support the protective effects of Th2 mediated disorders on Th1 immune responses seen in MS. Worse psychological symptoms can be attributed to cholinergic /beta adrenergic deregulation identified in patients with allergies. Additional prospective studies are required to elucidate these relationships.Disclosure: Dr. Gupta has nothing to disclose. Dr. Kavak has nothing to disclose. Dr. Teter has received research support from Biogen Idec, EMD Serono, Novartis, and Genzyme Corp. Dr. Weinstock-Guttman has received personal co...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Gupta, S., Kavak, K., Teter, B., Weinstock-Guttman, B. Tags: Multiple Sclerosis Symptoms and Comorbidities Source Type: research

Smoking in Multiple Sclerosis Patients is Negatively Associated with Patient Perceived Psychosocial Factors (P6.177)
Conclusion: Smokers with MS had lower levels of self-reported mood state compared to non-smokers. The direction of the association cannot be determined, as people with psychosocial problems might be more likely to smoke. Gaining more insight into the outcomes of smoking among MS patients may lead to further interventions and influence the wellbeing of people with MS.Disclosure: Dr. Kavak has nothing to disclose. Dr. Teter has received research support from Biogen Idec, EMD Serono, Novartis, and Genzyme Corp. Dr. Weinstock-Guttman has received personal compensation for activities with Biogen Idec, Teva Neuroscience, EMD Ser...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Kavak, K., Teter, B., Weinstock-Guttman, B. Tags: Multiple Sclerosis Symptoms and Comorbidities Source Type: research

Subcutaneous Interferon Beta-1a Decreases the Evolution of Gadolinium-Enhancing Lesions Into Chronic Black Holes in Relapsing Multiple Sclerosis (P7.240)
CONCLUSIONS: sc IFN beta-1a was associated with a decreased proportion of new Gd+ lesions evolving into CBHs, particularly in patients with lower disability scores.Study Support: Merck Serono SA Geneva, Switzerland, a subsidiary of Merck KGaA, Darmstadt, GermanyDisclosure: Dr. Traboulsee has received personal compensation for activities with Roche Diagnostics Corp., EMD Serono, Teva Neuroscience, and Biogen Idec. Dr. Traboulsee has received research support from Bayer Pharmaceuticals Corp., and Roche Diagnostics Corp. Dr. Li has received personal compensation for activities with Opexa, Nuron, Genzyme Corp., Roche Diagnosti...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Traboulsee, A., Li, D., Zhao, Y., Tam, R., Zhao, G., Cheng, Y., Riddehough, A., Dangond, F., Fang, J., Kappos, L. Tags: Multiple Sclerosis and CNS Inflammatory Diseases: Treatment Source Type: research

Social Cognition in Pediatric Multiple Sclerosis (MS) (S33.006)
CONCLUSIONS: Findings suggest that over short time frames, stable or even improved performances on measures of cognitive ability can occur in pediatric MS. Rather than leading to decline, pediatric MS may instead adversely affect cognitive functioning by interfering with expected age-appropriate gains.Study Supported by: The Lourie Foundation, Inc., National Multiple Sclerosis Society (PP2106), National Multiple Sclerosis Society (10020073405), NIH R01N5071463, and the Slomo and Cindy Silvian Foundation.Disclosure: Dr. Charvet has received personal compensation for activities with Biogen Idec as a consultant. Dr. Charvet h...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Charvet, L., Cleary, R., Vazquez, K., Koznesoff, L., Bartolotta, K., Benhamroun, J., Krupp, L. Tags: Cognition Fatigue in Multiple Sclerosis Source Type: research

Measuring Enduring Worsening Of Multiple Sclerosis In The CombiRx Study (S34.007)
CONCLUSIONS: This study demonstrates that of the various measures of worsening, 6 month confirmed increase of EDSS occurred more frequently than the other metrics, but was less durable than some. The 1+1 assessment produced the greatest percentage worsening from baseline and was the most durable metric. Ever reaching EDSS 6 had similarly good durability and second best percentage ending study above baseline. Once correlated with relapse activity, these assessments may serve as a basis for defining secondary progressive MS.Study Supported by: NIH/NINDS NS045719Disclosure: Dr. Lublin has received personal compensation for ac...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lublin, F., Cofield, S., Nelson, F., Narayana, P., Gustafson, T., Wolinsky, J., Cutter, G. Tags: MS and CNS Inflammatory Disease: Risk Factors for Multiple Sclerosis Disease and Course Source Type: research

A Combination Trial of Estriol Plus Glatimer Acetate in Relapsing-Remitting Multiple Sclerosis (I7-2.002)
CONCLUSIONS: Effects of treatment of RRMS women with a dose of estriol to induce a pregnancy level in serum will be discussed in the context of future development of estriol as a novel treatment in MS, and insights in understanding disease protection during pregnancy will be explored.Disclosure: Dr. Voskuhl has received personal compensation for activities with Synthetic Biologics Inc. Dr. Voskuhl has received license fee payments from UCLA. Dr. Voskuhl has received research support from Synthetic Biologics, and Karo Bio. Dr. Wang has nothing to disclose. Dr. Wu has nothing to disclose. Dr. Sicotte has nothing to disclose....
Source: Neurology - April 9, 2014 Category: Neurology Authors: Voskuhl, R., Wang, H., Wu, T. C. J., Sicotte, N., Bates, A., Beaver, G., Corboy, J., Cross, A., Dhib-Jalbut, S., Ford, C., Giesser, B., Jacobs, D., Lynch, S., Pachner, A., Racke, M., Ratchford, J., Reder, A., Rose, J., Wingerchuk, D., Burnett, M., Tseng, Tags: Emerging Therapeutic Advances in Multiple Sclerosis Data Blitz Presentations Source Type: research

Isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis
We report a very rare oculomotor disorder due to a demyelinating central nervous system (CNS) lesion in the medial part of the lower pontine tegmentum. A 36-year-old man presented with sudden onset of blurred vision. Clinically there was limited eye adduction and abduction to either side, which corresponds to bilateral horizontal gaze palsy. Brain magnetic resonance imaging (MRI) showed a demyelinating CNS lesion affecting the fasciculus longitudinalis medialis, abducens nuclei or abducens fibres in the medial part of the lower pontine tegmentum. Furthermore there were six further demyelinating white matter lesions fulfill...
Source: Multiple Sclerosis - April 22, 2014 Category: Neurology Authors: Kipfer, S., Crook, D. W. Tags: Case Study Source Type: research

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
Conclusions Currently available IL-21 ELISA kits should not be used to counsel individuals with multiple sclerosis considering treatment with alemtuzumab.
Source: Journal of Neurology, Neurosurgery and Psychiatry - June 10, 2014 Category: Neurosurgery Authors: Azzopardi, L., Thompson, S. A. J., Harding, K. E., Cossburn, M., Robertson, N., Compston, A., Coles, A. J., Jones, J. L. Tags: Immunology (including allergy), Multiple sclerosis Source Type: research